Paloma Partners Management CO Biomarin Pharmaceutical Inc Transaction History

Paloma Partners Management CO

$3.28 Billion
Q2 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $13,158 - $15,543	157 Added 59.47%	421 $36,000
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $119,665 - $154,660	-1,570 Reduced 85.61%	264 $25,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $156,018 - $173,276	1,834 New	1,834 $162,000
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $663,442 - $782,790	-8,075 Reduced 76.0%	2,550 $216,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $475,699 - $577,986	6,655 Added 167.63%	10,625 $881,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $294,891 - $367,979	3,970 New	3,970 $306,000
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $876,827 - $1 Million	-11,727 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $246,011 - $276,245	-3,258 Reduced 21.74%	11,727 $979,000
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $575,944 - $698,947	7,707 Added 105.89%	14,985 $1.13 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $1.97 Million - $2.45 Million	-27,179 Reduced 78.88%	7,278 $639,000
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $2.31 Million - $4.21 Million	32,157 Added 1398.13%	34,457 $2.62 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $246,605 - $385,082	-3,100 Reduced 57.41%	2,300 $284,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $129,679 - $175,976	1,817 Added 50.71%	5,400 $456,000
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $1.4 Million - $1.88 Million	-21,716 Reduced 85.84%	3,583 $303,000
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $1.45 Million - $1.83 Million	21,555 Added 575.72%	25,299 $1.71 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $1.4 Million - $1.64 Million	-17,485 Reduced 82.36%	3,744 $320,000
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $1.54 Million - $1.8 Million	18,270 Added 617.44%	21,229 $1.89 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $352,375 - $466,389	-4,397 Reduced 59.77%	2,959 $253,000
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $228,319 - $257,005	2,431 Added 49.36%	7,356 $713,000
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $419,043 - $545,952	-5,513 Reduced 52.82%	4,925 $464,000
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $204,738 - $244,172	2,636 Added 33.79%	10,438 $847,000
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $24,308 - $28,634	-301 Reduced 3.71%	7,802 $696,000
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $653,101 - $769,379	8,103	8,103 $754,000

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

Black Rock Inc. New York, NY

22.7M
Shares

$1.6 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$1.34 Billion
0.03% of portfolio
Primecap Management CO Pasadena, CA

18.8M
Shares

$1.33 Billion
1.14% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$983 Million
0.72% of portfolio
Capital Research Global Investors Los Angeles, CA

9.69M
Shares

$684 Million
0.18% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.

Account